Cardiac allograft vasculopathy prevention: Difference between revisions
No edit summary |
|||
| Line 19: | Line 19: | ||
* [[Mycophenolate mofetil]] | * [[Mycophenolate mofetil]] | ||
===[[Immunosuppressive drugs#Drugs Acting on Immunophilins|Calcineurin inhibitors]]=== | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 19:30, 1 October 2014
|
Cardiac allograft vasculopathy Microchapters |
|
Differentiating Cardiac allograft vasculopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cardiac allograft vasculopathy prevention On the Web |
|
American Roentgen Ray Society Images of Cardiac allograft vasculopathy prevention |
|
Directions to Hospitals Treating Cardiac allograft vasculopathy |
|
Risk calculators and risk factors for Cardiac allograft vasculopathy prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]
Overview
Prevention
As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy.
Optimization of Immunosuppressive Therapy
Options for immunosuppressive therapy for prevention of CAV include:
- Calcineurin inhibitors, such as
- Sirolimus (Rapamycin)
- Everolimus, a Rapamycin derivative
- Corticosteroids
- Azathioprine
- Mycophenolate mofetil